Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2022
Reporting Period: The filing references financial results for the three months ended June 30, 2022, announced via a press release on August 3, 2022.
Key Financial Metrics
The provided text is a cover sheet and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not list specific values within this document.
- Revenue, Profit, Cash Flow, Margins: Not provided in this text; contained in the referenced press release.
- Debt and Liquidity: Not provided in this text; contained in the referenced press release.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2022.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a conference call to be held at 8:00 AM ET on August 4, 2022, to discuss the results.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release issued August 3, 2022) for specific revenue, net income, and cash flow figures.
- Verify the details of the conference call held on August 4, 2022, for management's outlook and commentary.
- Confirm the specific reasons for any material changes in financial condition by cross-referencing the Q2 2022 results with Q2 2021 data found in the full press release.